Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Adams Brian
 2. Date of Event Requiring Statement (Month/Day/Year)
03/10/2015		 3. Issuer Name and Ticker or Trading Symbol
KERYX BIOPHARMACEUTICALS INC [KERX]
(Last)
(First)
(Middle)
C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
General Counsel
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEW YORK, NY 10022		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock (Restricted) 40,000 (1)
D
 
Common Stock (Restricted) 23,875 (2)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) 04/14/2015(3) 04/14/2024 Common Stock 60,000 $ 14.06 D  
Stock Options (Right to Buy) 01/04/2016(4) 01/04/2025 Common Stock 47,750 $ 14.34 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Adams Brian
C/O KERYX BIOPHARMACEUTICALS, INC.
750 LEXINGTON AVENUE
NEW YORK, NY 10022		       General Counsel  

Signatures

/s/ James F. Oliviero, Attorney-in-Fact 03/16/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The 40,000 shares are restricted common stock, with one-third of the 40,000 shares vesting on April 14, 2015, and one-twelfth vesting on each of July 14, 2015, October 14, 2015, January 14, 2016, April 14, 2016, July 14, 2016, October 14, 2016, January 14, 2017and April 14, 2017.
(2) The 23,875 shares are restricted common stock, with one-third of the 23,875 shares vesting on January 4, 2016, and one-twelfth vesting on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018.
(3) The options vest according to the following schedule: one-third of the 60,000 options vesting on April 14, 2015, and one-twelfth vesting on each of July 14, 2015, October 14, 2015, January 14, 2016, April 14, 2016, July 14, 2016, October 14, 2016, January 14, 2017and April 14, 2017.
(4) The options vest according to the following schedule: one-third of the 47,750 options will vest on January 4, 2016, and one-twelfth will vest on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.